Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 12-05-2019, 07:40 PM #1
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default Results out on the NILO-PD trial of Nilotinib

Results of the NILO-PD (Northwestern University) phase 2 trial of Nilotinib show the drug to be safe & tolerable. Unfortunately, it did not demonstrate any benefit for Parkinson's symptoms or biological measures. Basically, it doesn't have very good BBB penetration. Trials will begin on several other c-Abl inhibitors which appear to have better brain penetration.

There will be a webinar on Dec. 17th where more detail will be provided and questions answered.

Though safe, nilotinib does not show promise for benefit for Parkinson's disease
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
anagirl (12-12-2019), jeffreyn (12-06-2019), johnt (12-06-2019), olsen (12-06-2019), soccertese (12-06-2019), TheDub1 (12-26-2019)

advertisement
Old 12-11-2019, 01:28 PM #2
ashleyk ashleyk is offline
Member
 
Join Date: Oct 2006
Location: New England
Posts: 262
15 yr Member
ashleyk ashleyk is offline
Member
 
Join Date: Oct 2006
Location: New England
Posts: 262
15 yr Member
Default curcumin

I am disappointed, again, that another clinical trial seems to have failed. Curcumin does seem to have an effect on a-aynuclein. It's easy to buy and should be safe.





Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice



The curry spice curcumin plays a protective role in mouse models of neurodegenerative diseases, and can also directly modulate aggregation of α-synuclein protein in vitro, yet no studies have described the interaction of curcumin and α-synuclein in genetic synucleinopathy mouse models. Here we examined the effect of chronic and acute curcumin treatment in the Syn-GFP mouse line, which overexpresses wild-type human α-synuclein protein. We discovered that curcumin diet intervention significantly improved gait impairments and resulted in an increase in phosphorylated forms of α-synuclein at cortical presynaptic terminals. Acute curcumin treatment also caused an increase in phosphorylated α-synuclein in terminals, but had no direct effect on α-synuclein aggregation, as measured by in vivo multiphoton imaging and Proteinase-K digestion. Using LC-MS/MS, we detected ~5 ng/mL and ~12 ng/mL free curcumin in the plasma of chronic or acutely treated mice, with a glucuronidation rate of 94% and 97%, respectively. Despite the low plasma levels and extensive metabolism of curcumin, these results show that dietary curcumin intervention correlates with significant behavioral and molecular changes in a genetic synucleinopathy mouse model that mimics human disease.
ashleyk is offline   Reply With QuoteReply With Quote
Old 12-16-2019, 02:05 PM #3
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default

Georgetown has reported the results of their Nilotinib clinical trial. They may interpret the data differently, however, the results really are quite similar to the Northwestern trial. I believe they are hopping to get support for a phase 3. I honestly think, though, that given the limited amount of research dollars available, the funds would be better used to research the other three c-abl inhibitors that are going into trial. They all have better neurological profiles than nilotinib.

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial | Movement Disorders | JAMA Neurology | JAMA Network
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
jeffreyn (12-16-2019), soccertese (12-17-2019)
Reply

Tags
nilo-pd, nilotinib, penetration, results, trial


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
New pharmacokinetics and biomarker data from the Georgetown Nilotinib trial Tupelo3 Parkinson's Disease 3 03-14-2019 02:06 PM
Nilotinib in Parkinson's Disease (NILO-PD) badboy99 Parkinson's Disease 13 11-06-2017 02:45 PM
Georgetown Receives FDA Clearance for Trial with Nilotinib in Alzheim zanpar321 Parkinson's Disease 10 10-07-2016 08:46 PM
Nilotinib Parkinson Trial to begin this summer! zanpar321 Parkinson's Disease 1 07-28-2016 12:25 PM
Six month follow up on Nilotinib trial. Betsy859 Parkinson's Disease 30 07-17-2016 05:52 PM


All times are GMT -5. The time now is 06:25 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.